JP2007538108A5 - - Google Patents

Download PDF

Info

Publication number
JP2007538108A5
JP2007538108A5 JP2007527588A JP2007527588A JP2007538108A5 JP 2007538108 A5 JP2007538108 A5 JP 2007538108A5 JP 2007527588 A JP2007527588 A JP 2007527588A JP 2007527588 A JP2007527588 A JP 2007527588A JP 2007538108 A5 JP2007538108 A5 JP 2007538108A5
Authority
JP
Japan
Prior art keywords
composition
polypeptide
administered
subject
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007527588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007538108A (ja
JP4982373B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/019126 external-priority patent/WO2005113001A1/en
Publication of JP2007538108A publication Critical patent/JP2007538108A/ja
Publication of JP2007538108A5 publication Critical patent/JP2007538108A5/ja
Application granted granted Critical
Publication of JP4982373B2 publication Critical patent/JP4982373B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007527588A 2004-05-20 2005-05-20 Il−21およびモノクローナル抗体治療を用いる癌を処置する方法 Expired - Fee Related JP4982373B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US57297304P 2004-05-20 2004-05-20
US60/572,973 2004-05-20
US63538004P 2004-12-10 2004-12-10
US60/635,380 2004-12-10
US67128105P 2005-04-14 2005-04-14
US60/671,281 2005-04-14
US68044705P 2005-05-12 2005-05-12
US60/680,447 2005-05-12
PCT/US2005/019126 WO2005113001A1 (en) 2004-05-20 2005-05-20 Methods of treating cancer using il-21 and monoclonal antibody therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011284589A Division JP2012102122A (ja) 2004-05-20 2011-12-27 Il−21およびモノクローナル抗体治療を用いる癌を処置する方法

Publications (3)

Publication Number Publication Date
JP2007538108A JP2007538108A (ja) 2007-12-27
JP2007538108A5 true JP2007538108A5 (https=) 2008-07-10
JP4982373B2 JP4982373B2 (ja) 2012-07-25

Family

ID=34971701

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007527588A Expired - Fee Related JP4982373B2 (ja) 2004-05-20 2005-05-20 Il−21およびモノクローナル抗体治療を用いる癌を処置する方法
JP2011284589A Ceased JP2012102122A (ja) 2004-05-20 2011-12-27 Il−21およびモノクローナル抗体治療を用いる癌を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011284589A Ceased JP2012102122A (ja) 2004-05-20 2011-12-27 Il−21およびモノクローナル抗体治療を用いる癌を処置する方法

Country Status (15)

Country Link
US (8) US20050265966A1 (https=)
EP (4) EP2428216A3 (https=)
JP (2) JP4982373B2 (https=)
KR (1) KR101236177B1 (https=)
CN (2) CN103127502A (https=)
AU (1) AU2005245031B2 (https=)
BR (1) BRPI0511187A (https=)
CA (1) CA2566745A1 (https=)
CY (1) CY1113287T1 (https=)
DK (1) DK1758610T3 (https=)
ES (1) ES2390278T3 (https=)
IL (1) IL179099A (https=)
PL (1) PL1758610T3 (https=)
PT (1) PT1758610E (https=)
WO (1) WO2005113001A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
BRPI0511187A (pt) * 2004-05-20 2007-12-04 Zymogenetics Inc método para tratar cáncer em um indivìduo
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
KR100902340B1 (ko) * 2007-08-02 2009-06-12 한국생명공학연구원 Yc-1 또는 il-21을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
US8506933B2 (en) * 2007-11-30 2013-08-13 Msdx, Inc. Methods of detecting a neurological condition via analysis of circulating phagocytes
WO2011019670A1 (en) * 2009-08-10 2011-02-17 Nayak Ramesh C Methods of detecting responses to therapies using perforin levels
EP2504699A1 (en) * 2009-11-27 2012-10-03 MSDX, Inc. Methods of detecting or monitoring activity of an inflammatory or neurodegenerative condition
US8673309B2 (en) 2011-02-11 2014-03-18 Msdx, Inc. Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1
US9447160B2 (en) * 2012-01-19 2016-09-20 University Of Miami Compositions, methods and kits for treatment of cancer and autoimmune diseases
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
HUE051676T2 (hu) 2014-04-08 2021-03-29 Boston Pharmaceuticals Inc Il-21-re specifikus kötõ molekulák és alkalmazásaik
KR20160120157A (ko) 2015-04-07 2016-10-17 주식회사 메드팩토 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
US20200016200A1 (en) * 2016-10-03 2020-01-16 Baylor College Of Medicine Modulating cytotoxic cell lytic granule positioning to promote diffuse killing in cellular therapies
EP3682237A1 (en) * 2017-09-15 2020-07-22 Beckman Coulter, Inc. Flow based assays for therapeutics
KR102265437B1 (ko) * 2017-11-24 2021-06-15 의료법인 성광의료재단 Nk 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
CA2340091C (en) * 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2001001748A2 (en) * 1999-07-02 2001-01-11 Genentech, Inc. Peptide compounds that bind her2
IT1311703B1 (it) 1999-07-23 2002-03-19 Sipa Spa Impianto ad alta efficienza di soffiaggio di preforme
ES2279809T3 (es) 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
JP2005538034A (ja) 2001-12-07 2005-12-15 カイロン コーポレイション 非ホジキンリンパ腫の治療方法
KR101033196B1 (ko) * 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-cd20 항체 및 그 융합 단백질 및 이들의 이용방법
BR0309254A (pt) * 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
MXPA04012116A (es) * 2002-06-07 2005-04-19 Zymogenetics Inc Uso del il-21 en cancer y otras aplicaciones terapeuticas.
CN101972478B (zh) * 2002-10-08 2012-10-31 免疫医疗公司 抗体治疗
US20070092485A1 (en) * 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
ES2334127T3 (es) * 2002-12-13 2010-03-05 Zymogenetics, Inc. Produccion de il-21 en huespedes procariotas.
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
JP2007508332A (ja) * 2003-10-17 2007-04-05 ノボ ノルディスク アクティーゼルスカブ 併用療法
BRPI0511187A (pt) * 2004-05-20 2007-12-04 Zymogenetics Inc método para tratar cáncer em um indivìduo
WO2006065495A2 (en) * 2004-11-24 2006-06-22 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens

Similar Documents

Publication Publication Date Title
JP2007538108A5 (https=)
US20240009196A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
Mikulska et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)
TWI784983B (zh) 可活化之抗ctla-4抗體及其用途
CN104379602B (zh) 具有条件活性的抗表皮生长因子受体抗体及其使用方法
AU2004308749B2 (en) CD40 antibody formulation and methods
JP6282745B2 (ja) 修飾抗上皮成長因子受容体抗体およびその使用法
JP2013539352A5 (https=)
JP2022513420A5 (https=)
AU2022202800B2 (en) Combinations and uses thereof
JP2020504723A5 (https=)
CN102216332A (zh) 抗-cs1抗体用于治疗罕见淋巴瘤的用途
JP2009533367A5 (https=)
JP2011507932A5 (https=)
JP2009541492A5 (https=)
WO2017161206A1 (en) Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
JP2009518441A5 (https=)
CN112839962A (zh) 用于治疗癌症的抗mertk抗体
SI2125897T1 (en) MONOCOLONIAL PROTITELES AGAINST GT 468 FOR CARRYING CANCER
JP2015517511A (ja) Cd37抗体とice(イフォスファミド、カルボプラチン、エトポシド)の併用
Robak et al. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia
JP2020528061A (ja) BET阻害剤、Bcl−2阻害剤及び抗CD20抗体を用いた併用療法
CN111973739A (zh) 抗pd-l1单克隆抗体治疗癌症的用途
Zhou et al. Mechanism of action for therapeutic antibodies
JP2024511831A (ja) 抗原結合タンパク質およびそれらの組み合わせ